Phaseline

Companies › Iterum Therapeutics, International

Iterum Therapeutics, International: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sulopenem
Bacterial penicillin-binding protein inhibitor
UNKNOWNPhase 1Pharmacokinetics After Oral Intake–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07092813SulopenemPhase 1Pharmacokinetics After Oral IntakeOtherOct 2026

Targets

UNKNOWN (1)

Companies with the same targets

General Oncology Gilead Sciences Colgate Palmolive Vaxcyte Zhejiang Raygene Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.